RecruitingPhase 1NCT07037862

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Entrada Therapeutics, Inc.
Principal Investigator
Entrada Therapeutics Clinical Trials
Entrada Therapeutics, Inc.
Intervention
ENTR-601-44(drug)
Enrollment
24 enrolled
Eligibility
4-20 years · MALE
Timeline
20252029

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07037862 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials